This Innovative Biotech Firm Is Changing The Way We See Medication

Sign up for this week’s All Access giveaway here!

Dr. Lynn Kirkpatrick, CEO of Ensysce Biosciences ENSC, was a guest on Benzinga’s All Access on Sep 23, 2022. 

Ensysce is a biotech company committed to stemming the prescription drug abuse epidemic. The company focuses on innovative chemistry to meet research & development goals. Its approach is to look at drug delivery from a different view, using sophisticated chemistry to change the mode of activation rather than just modify a formulation.

Watch the full interview here:

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechPenny StocksExclusivesInterviewGeneralBenzinga All AccessPartner Content
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!